Pfizer plans to sell some cardiovascular, urinary and care products for $2 billion
Pfizer plans to sell some mature cardiovascular, urinary and primary care products for $2 billion, with annual sales totaling approximately $700 million. Pfizer has hired JP Morgan, the big investment bank, to find potential buyers. According to the report, 40% of the sales revenue of these products comes from the US market, and 45% comes from the European market. Pfizer plans to package these products for sale instead of selling them alone, and pharmaceutical companies and private equity firms are potential buyers. In October last year, Pfizer announced that it would no longer consider splitting generic drugs and patented drugs into two separate companies, arguing that the split has a positive effect on its cash flow and market competitiveness. However, Pfizer did not expressly say that it will not strip some mature products. In particular, Pfizer recently announced a $5 billion stock repurchase program, which makes the rumors of selling some mature products more credible. Pfizer acquired Hospira for $15 billion in 2015 and is still digesting this part of the sterile injection business. However, according to the information disclosed in the 2016Q4 quarterly report, Pfizer's willingness to acquire and expand pipelines remains strong after the acquisition of Anacor and Medivation in 2016. Foot Spa Massager,Bath Foot Massager Machine,Foot Spa Bath,Bath Foot Massager With Bubble Huaian Mimir Electric Appliance Co., LTD , https://www.mmfootspa.com